Home › Pfizer's Ibrance drug slows progression of breast cancer
 

Keywords :   


Pfizer's Ibrance drug slows progression of breast cancer

2015-05-30 19:03:57| Biotech - Topix.net

CHICAGO: A Phase III trial of Pfizer Inc's drug Ibrance showed that, in combination with hormone therapy, the drug more than doubled the duration of disease control for women with the most common type of breast cancer. At the time of an interim analysis, patients given Ibrance in combination with AstraZeneca Plc's Faslodex , a widely used treatment to block estrogen, lived an average of 9.2 months before their cancer worsened.

Tags: drug cancer breast progression

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
02.07M13 Graphics invests in Landa digital press
02.07ABG helps Nordvalls increase productivity
02.07Tesla sales rise sharply after slump
02.07Hurricane Beryl Graphics
02.07Hurricane Beryl Forecast Discussion Number 16
02.07Fedrigoni teams with Progetto Quid
02.07Hurricane Beryl Forecast Advisory Number 16
02.07Hurricane Beryl Public Advisory Number 16
More »